GoAI
Get started
AbbVie Inc. logo

AbbVie Inc.

ABBV

NYSEHealthcareDrug Manufacturers - General

Open in GoAI

Previous close

$265.01

+$3.18 · +1.21%

Aug 21, 3:59 PM ET

ABBV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

18

Overpriced

Momentum

57

Neutral

Sentiment

70

Bullish

Risk resilience

81

Low Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $265.01

52-week range

Current $265.01

Open
$260.7
Previous close
$261.83
Volume
5.13M
Market cap
468.22B USD
50-day average
$247.19
+7.21% above average
200-day average
$226.3
+17.11% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
469.18B USD
P/E (TTM)
74.66×
P/B (TTM)
-79.08×
P/S (TTM)
7.27×
EV / EBITDA
26.61×
Earnings yield
1.04%
Free cash flow yield
4.40%
Dividend yield
2.58%

Profitability & efficiency

Gross margin
71.48%
Operating margin
29.32%
Net margin
9.81%
Return on equity
-129.24%
Return on assets
3.15%
Return on invested capital
12.97%

Financial health

Debt / equity
-11.93×
Current ratio
0.67×
Altman Z-score
2.54
Piotroski F-score
9 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends77%51%26%1%Gross margin, FY2021: 68.96%Gross margin, FY2022: 70.00%Gross margin, FY2023: 62.42%Gross margin, FY2024: 69.99%Gross margin, FY2025: 70.24%Operating margin, FY2021: 31.89%Operating margin, FY2022: 31.21%Operating margin, FY2023: 23.49%Operating margin, FY2024: 16.22%Operating margin, FY2025: 32.85%Net margin, FY2021: 20.54%Net margin, FY2022: 20.39%Net margin, FY2023: 8.95%Net margin, FY2024: 7.59%Net margin, FY2025: 6.91%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.96%. Gross margin FY2022 70.00%. Gross margin FY2023 62.42%. Gross margin FY2024 69.99%. Gross margin FY2025 70.24%. Operating margin FY2021 31.89%. Operating margin FY2022 31.21%. Operating margin FY2023 23.49%. Operating margin FY2024 16.22%. Operating margin FY2025 32.85%. Net margin FY2021 20.54%. Net margin FY2022 20.39%. Net margin FY2023 8.95%. Net margin FY2024 7.59%. Net margin FY2025 6.91%.

Income trends

Revenue

61.16B USD+8.57%

Operating income

20.09B USD+119.89%

Net income

4.23B USD-1.22%
Income trends across reported periods66.85B USD44.08B USD21.31B USD−1.47B USDRevenue, FY2021: 56.2B USDRevenue, FY2022: 58.05B USDRevenue, FY2023: 54.32B USDRevenue, FY2024: 56.33B USDRevenue, FY2025: 61.16B USDOperating income, FY2021: 17.92B USDOperating income, FY2022: 18.12B USDOperating income, FY2023: 12.76B USDOperating income, FY2024: 9.14B USDOperating income, FY2025: 20.09B USDNet income, FY2021: 11.54B USDNet income, FY2022: 11.84B USDNet income, FY2023: 4.86B USDNet income, FY2024: 4.28B USDNet income, FY2025: 4.23B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 56.2B USD. Revenue FY2022 58.05B USD. Revenue FY2023 54.32B USD. Revenue FY2024 56.33B USD. Revenue FY2025 61.16B USD. Operating income FY2021 17.92B USD. Operating income FY2022 18.12B USD. Operating income FY2023 12.76B USD. Operating income FY2024 9.14B USD. Operating income FY2025 20.09B USD. Net income FY2021 11.54B USD. Net income FY2022 11.84B USD. Net income FY2023 4.86B USD. Net income FY2024 4.28B USD. Net income FY2025 4.23B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue61.16B USD56.33B USD54.32B USD58.05B USD56.2B USD
Cost of goods sold18.2B USD16.9B USD20.42B USD17.41B USD17.45B USD
Gross profit42.96B USD39.43B USD33.9B USD40.64B USD38.75B USD
Research and development9.1B USD12.79B USD7.68B USD6.51B USD8.05B USD
Selling, general, and administrative14.01B USD14.75B USD12.87B USD15.26B USD12.35B USD
Operating expenses22.87B USD30.29B USD21.15B USD22.52B USD20.83B USD
Interest income266M USD648M USD540M USD186M USD39M USD
Interest expense2.89B USD2.81B USD2.22B USD2.23B USD2.42B USD
Depreciation and amortization8.14B USD8.39B USD8.7B USD8.47B USD8.52B USD
Operating income20.09B USD9.14B USD12.76B USD18.12B USD17.92B USD
Net income4.23B USD4.28B USD4.86B USD11.84B USD11.54B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
-0.10%
11 comparable reports
Latest EPS result
3.65
Estimate 3.61 · Beat by 1.11%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates4.033.222.411.6Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 2.16, estimate 2.98, surprise -27.52%, Miss. Q2 2025, reported Apr 25, 2025: actual 2.46, estimate 2.38, surprise +3.36%, Beat. Q3 2025, reported Jul 31, 2025: actual 2.97, estimate 2.88, surprise +3.13%, Beat. Q4 2025, reported Oct 31, 2025: actual 1.86, estimate 1.77, surprise +5.08%, Beat. Q1 2026, reported Feb 4, 2026: actual 2.71, estimate 2.65, surprise +2.26%, Beat. Q2 2026, reported Apr 29, 2026: actual 2.65, estimate 2.59, surprise +2.32%, Beat. Q3 2026, reported Jul 31, 2026: actual 3.65, estimate 3.61, surprise +1.11%, Beat. Q4 2026, reported Oct 30, 2026: actual —, estimate 3.86, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates18B16.08B14.16B12.23BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 15.1B USD, estimate 14.83B USD, surprise +1.82%, Beat. Q2 2025, reported Apr 25, 2025: actual 13.34B USD, estimate 12.93B USD, surprise +3.22%, Beat. Q3 2025, reported Jul 31, 2025: actual 15.42B USD, estimate 15.03B USD, surprise +2.62%, Beat. Q4 2025, reported Oct 31, 2025: actual 15.78B USD, estimate 15.59B USD, surprise +1.22%, Beat. Q1 2026, reported Feb 4, 2026: actual 16.62B USD, estimate 16.41B USD, surprise +1.25%, Beat. Q2 2026, reported Apr 29, 2026: actual 15B USD, estimate 14.72B USD, surprise +1.93%, Beat. Q3 2026, reported Jul 31, 2026: actual 16.99B USD, estimate 16.8B USD, surprise +1.11%, Beat. Q4 2026, reported Oct 30, 2026: actual —, estimate 17.31B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$285.92

7.89% upside
Past 12 months12-month forecastHigh $303Average $285.92Low $235

Rating distribution

42 ratings
Strong buy00%
Buy3071%
Hold1126%
Sell12%
Strong sell00%

Recent analyst actions

12 institutions
BNP ParibasmaintainNeutral

ABBV news

defenseworld.net

Gateway Wealth Partners LLC Cuts Position in AbbVie Inc. $ABBV

Gateway Wealth Partners LLC lowered its holdings in AbbVie Inc. (NYSE: ABBV) by 40.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,158 shares of the…

Read source
prnewswire.com

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new data and updates from…

Read source
247wallst.com

Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead

Dividend investors have had plenty to cheer in 2026. Pfizer (NYSE:PFE | PFE Price Prediction) is up 19.3% year to date, Chevron (NYSE:CVX) has surged 38.76%, and AbbVie (NYSE:ABBV) has added 19.16%.

Read source
247wallst.com

VYM Is Beating the S&P 500 With a 17% Year-to-Date Return by Owning What Wall Street Won’t

A mechanical yield screen is quietly outpacing the S&P 500 this year by excluding most of the AI complex before a single share is purchased, and the valuation gap it creates raises a question worth answering before the…

Read source
247wallst.com

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those…

Read source
defenseworld.net

AbbVie Inc. $ABBV Shares Sold by D.A. Davidson & CO.

D.A. Davidson and CO. reduced its stake in AbbVie Inc. (NYSE: ABBV) by 10.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional…

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$6.56

2025 complete year+26.2% since 2021

2026 partial: $5.19

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 15, 2026

$1.73

Quarterly

Record Jul 15, 2026 · Payment Aug 14, 2026

Dividend

Ex-dividend Apr 15, 2026

$1.73

Quarterly

Record Apr 15, 2026 · Payment May 15, 2026

Dividend

Ex-dividend Jan 16, 2026

$1.73

Quarterly

Record Jan 16, 2026 · Payment Feb 17, 2026

Dividend

Ex-dividend Oct 15, 2025

$1.64

Quarterly

Record Oct 15, 2025 · Payment Nov 14, 2025

Dividend

Ex-dividend Jul 15, 2025

$1.64

Quarterly

Record Jul 15, 2025 · Payment Aug 15, 2025

Dividend

Ex-dividend Apr 15, 2025

$1.64

Quarterly

Record Apr 15, 2025 · Payment May 15, 2025

ABBV peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

—

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

—

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

—

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

—

Novartis AG logo

NVS

Novartis AG

$158.86

—

AstraZeneca PLC logo

AZN

AstraZeneca PLC

$165.98

—

ETFs holding ABBV

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
14.12B
Weight
0.61%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard S&P 500 ETF logoVanguard S&P 500 ETFVOO
Market value
11.64B
Weight
0.69%
AUM
1.7T USD
Expense ratio
0.03%
Price / 1D
$703.71+0.39%
iShares Core S&P 500 ETF logoiShares Core S&P 500 ETFIVV
Market value
6.24B
Weight
0.70%
AUM
891.84B USD
Expense ratio
0.03%
Price / 1D
$769.31+0.39%
State Street SPDR S&P 500 ETF logoState Street SPDR S&P 500 ETFSPY
Market value
5.75B
Weight
0.70%
AUM
817.87B USD
Expense ratio
0.09%
Price / 1D
$765.72+0.41%
Vanguard Morningstar Value ETF logoVanguard Morningstar Value ETFVTV
Market value
4.22B
Weight
1.64%
AUM
256.5B USD
Expense ratio
0.03%
Price / 1D
$226.4+0.54%
State Street Health Care Select Sector SPDR ETF logoState Street Health Care Select Sector SPDR ETFXLV
Market value
3.33B
Weight
7.43%
AUM
44.76B USD
Expense ratio
0.08%
Price / 1D
$174.62+1.29%
Vanguard Dividend Appreciation ETF logoVanguard Dividend Appreciation ETFVIG
Market value
2.51B
Weight
1.91%
AUM
130.9B USD
Expense ratio
0.04%
Price / 1D
$243.91+0.69%
Vanguard High Dividend Yield ETF logoVanguard High Dividend Yield ETFVYM
Market value
1.79B
Weight
1.80%
AUM
99.2B USD
Expense ratio
0.04%
Price / 1D
$164.97+0.59%

Continue in GoAI

Research ABBV

research.disclaimer